A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

To join this study, you need to be an adult, aged 18 or older, and planning to have heart bypass surgery. This surgery must be planned in advance (not an emergency) and involve at least three 'bypasses,' which means creating three new routes for blood flow around your heart. Sometimes, this surgery also includes replacing a heart valve, and that's okay too.

There are also some important safety checks. For women who could become pregnant, you'll need to agree to use effective contraception (birth control) during and for a short time after the study medicine is given, and have a negative pregnancy test before starting. Men will also need to use contraception and not donate sperm for the same period. Everyone joining must be able to understand the study and agree to take part in writing.

However, some people won't be able to join. This includes if you're having emergency heart surgery, have very unstable heart health that needs strong medication or special devices just before surgery, or if you've recently needed CPR. People with severe liver disease or active serious infections won't be able to take part, nor will those with weakened immune systems. These rules are in place to make sure the study is as safe as possible for everyone involved.

If you decide to take part in this study, it will last for about 71 days in total, from the very beginning until your final check-up. Throughout this time, you'll have 10 appointments. Seven of these visits will happen while you're in the hospital for your surgery, and these will include checks related to the study. There will also be an initial screening visit to see if you can join, a visit just before your operation, and two follow-up visits that can be done remotely, meaning you might not need to come to the hospital for them.

During the study, you'll receive either the new medicine, EA-230, or a 'placebo' (a dummy treatment). You won't know which one you're getting, and neither will your doctors. This is called 'double-blind' and helps us get the most accurate results. The choice between EA-230 and the placebo is made completely by chance, like flipping a coin. You'll be closely monitored throughout your hospital stay and during the follow-up period to see how you're recovering and if the medicine is making a difference.